Company Overview - Siyata Mobile Inc is a B2B global developer and vendor of next-generation Push-To-Talk over Cellular (PoC) handsets and accessories, targeting first responders and enterprise workers [1] - The company's rugged PTT handsets and accessories enable instant communication over nationwide cellular networks, enhancing situational awareness and safety [1] - Siyata's products are utilized by various organizations including police, fire, ambulance services, schools, utilities, security companies, hospitals, waste management companies, and resorts [1] Product Portfolio and Distribution - Siyata offers enterprise-grade In-Vehicle solutions and Cellular Booster systems to support effective communication in vehicles and areas with weak cellular signals [4] - The company sells its portfolio through leading North American cellular carriers, as well as international cellular carriers and distributors [4] Strategic Collaboration - Siyata was cited in a press release by JVCKenwood, highlighting a collaboration that leverages JVCKenwood's extensive distribution network and brand recognition [3] - The collaboration aims to increase the reach of Siyata's devices in the US and Canada, broadening opportunities for device placements [3] - Kenwood Push-to-Talk over Cellular (PoC) Handsets will be showcased at major industry events including the NRF 2025 Expo and the World of Concrete Conference 2025 [3] Market Presence and Recognition - Siyata's common shares trade on the Nasdaq under the symbol "SYTA", and its warrants under the symbol "SYTAW" [2] - JVCKENWOOD Corp, a key collaborator, manufactures KENWOOD and Viking analog and digital two-way radios, providing turnkey system solutions for various markets including public safety, government, and healthcare [5]

Transaction Overview - Enstar Group Limited's Lloyd's syndicate (Syndicate 2008) has agreed to a ground-up loss portfolio transfer (LPT) with Atrium Syndicate 609, involving discontinued portfolios including Marine Treaty Reinsurance, Property Treaty Reinsurance, and US Contractors General Liability [1] - The transaction involves Atrium Syndicate 609 ceding net loss reserves of approximately $196 million to Enstar's Syndicate 2008, based on Atrium's carried reserves as of Q3 2024 [2] - The reinsurance covers business underwritten in 2023 and prior years, with all claims handling transferring to Syndicate 2008 [2] - The transaction is expected to complete in Q1 2025, pending regulatory approvals and customary closing conditions [2] Strategic Implications - The transaction allows Enstar to apply its specialist claims handling capabilities and bespoke solution approach to a portfolio in the Lloyd's marketplace [3] - Enstar maintains a strong relationship and partnership with Atrium, highlighting the company's focus on legacy solutions and strategic collaborations [3] Company Background - Enstar is a NASDAQ-listed global insurance group offering innovative capital release solutions through its network of companies in Bermuda, the US, the UK, Continental Europe, Australia, and other international locations [3] - Since its formation in 2001, Enstar has acquired over 120 companies and portfolios, establishing itself as a market leader in legacy acquisitions [3]

Reverse Stock Split - Mustang Bio Inc announced a 1-for-50 reverse stock split of its issued and outstanding common stock, effective from January 16, 2025 [1] - The reverse stock split was approved by the Board of Directors and stockholders representing approximately 56% of the voting power on June 27, 2024 [2] - The number of outstanding shares will be reduced from approximately 64.8 million to approximately 1.3 million, with no fractional shares issued and proportional cash payments made instead [3] Compliance and Trading Details - The reverse stock split aims to bring the company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing [2] - Mustang's common stock will continue to trade on Nasdaq under the symbol "MBIO" with a new CUSIP number of 62818Q302 [3] - VStock Transfer LLC is acting as the exchange and paying agent for the reverse stock split, providing instructions for physical share certificate exchanges [4] Company Overview - Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers [5] - The company partners with top medical institutions to advance CAR-T therapies and aims to license or acquire technologies for research and development [5] - Mustang was founded by Fortress Biotech Inc and its common stock is registered under the Securities Exchange Act of 1934 [5]

AUSTIN, Texas, Jan. 14, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The late ...

This funding underscores STACK’s financial strength and its ability to provide scalable digital infrastructure in key markets STACK Secures $900 Million in Green Financing in Northern Virginia This funding underscores STACK’s financial strength and its ability to provide scalable digital infrastructure in key markets. DENVER, Jan. 14, 2025 (GLOBE NEWSWIRE) -- STACK Infrastructure (“STACK”), the digital infrastructure partner to the world’s most innovative companies and a leading global developer and oper ...

WINSTON-SALEM, NC, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Inmar Intelligence, a leader in technology-driven solutions, announced the divestiture of its Supply Chain Solutions division to DHL Supply Chain. This strategic move allows Inmar to prioritize its Healthcare and Martech businesses by continuing to drive innovation and deliver enhanced value to customers and consumers in these rapidly evolving markets, as well as offering an opportunity to build upon Inmar’s long-standing leadership of returns solutions t ...

Collaboration will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney diseaseWARSAW, Poland, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies, today announced it has signed a distribution agreement with the MEDICE Health Family, a developer and provider of innovative, integrated, and multimodal healthcare solutions, t ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Enrollment ongoing in the United States for REGENERATE-PD clinical trial of AB-1005 (also known as AAV2-GDNF) glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy for the treatment of moderate-stage Parkinson’s diseasePhase Ib 36-month data demonstrated a favorable safety profile and continued positive trends in assessed clinical measures of AB-1005 with no associate ...

The deionized water system industry is poised for significant growth as sectors like pharmaceuticals, food & beverage, and electronics demand high-quality water. With innovation and customer-focused solutions, companies are set to capitalize on expanding market opportunities over the next decade.NEWARK, Del, Jan. 14, 2025 (GLOBE NEWSWIRE) -- According to a Future Market Insights (FMI), the deionized water system market is poised for substantial growth, with its estimated market value projected to increase f ...

Thought Leadership Initiative will Investigate How Prepared and Primed Organizations are to Unlock GenAI’s Next-Generation Business ValueSAN JOSE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- The Business Performance Innovation (BPI) Network and the Growth Officer Council today announced that they are teaming up with intelligent information management leader EncompaaS on a new initiative focused on assessing the state of data readiness in the rapid evolution of GenAI value creation. The new program, entitled “ ...